Mouse Models and PD Vaccines: Promising Results
Researchers used a mouse model for testing the influence of a vaccine on the loss of brain cells and neurodegeneration. Immune cells were taken from mice after injections of MPTP, a causative factor in neuronal degeneration. These cells were then treated with Copaxone, a drug commonly used to treat the inflammatory responses in MS. The researchers found that T cells in the treated mice migrated to the damaged area of the brain where they reduced the harmful reactions of the inflammatory microglia and dramatically increased the amount of glial-derived neurotrophic factor (GDNF) that helps prevent neurodegeneration. Source: [http://www.ninds.nih.org](http://www.ninds.nih.org)

Pergolide and Cardiac Abnormalities
A recent study reported that pergolide (Permax) use in PD might be associated with cardiac valve regurgitation. Echocardiograms were obtained on 46 patients receiving pergolide and compared with those from an age-matched control group taken from the Framingham Study. A composite valve regurgitation score was modeled as a linear function of total milligrams lifetime use of pergolide, controlling for age. 89% of pergolide-treated patients had some degree of valvular insufficiency, particularly tricuspid and cardiac. Source: [http://www.neurology.org/cgi/content/abstract/63/2/301](http://www.neurology.org/cgi/content/abstract/63/2/301)

Parkinson's Disease, Psychosis and Comorbidities
Twenty-five patients with PD and psychotic symptoms, divided into two groups, were compared with 25 PD patients without psychiatric comorbidities. There were no differences in age, sex, education, age of onset, or duration of illness among the 3 groups. Both psychotic groups had greater motor, functional, and frontal cognitive deficits than the control group. Psychosis was a primary predictor of caregiver burden, whereas depressive symptoms indirectly enhanced motor impairments. Nonpsychotic psychiatric disturbances, especially affective problems, are common comorbidities in PD and deserve expert clinical attention to reduce morbidity and caregiver distress.
Pramipexole versus Levodopa
Twenty-two PD Study Group sites in the US and Canada evaluated 301 subjects in a four-year study comparing treatments in early PD. Pramipexole (Mirapex) resulted in a greater reduction of dyskinesias, drug wearing off, and on-off fluctuations. Initial treatment of levodopa resulted in a lower incidence of freezing, somnolence, edema, and better motor performance. The primary outcome was measured as the amount of time to the first occurrence of dopaminergic motor complications. After 4 years, over 50% of pramipexole subjects reached the primary endpoint as compared with almost 75% of the levodopa subjects. UPDRS scores were more improved in the levodopa group. (Boehringer/Ingelheim Pharmaceuticals, Inc. & Pfizer, Inc supported this study).

Source: [http://www.neurology.org/cgi/content/abstract/63/2/301](http://www.neurology.org/cgi/content/abstract/63/2/301)

Parkinson's Disease and Twins
Over 33,000 twins from the Swedish Twin Registry were interviewed by phone about the presence of movement disorders. 247 twins self-reported PD or a PD diagnosis and 517 others reported parkinsonian symptoms or the use of antiparkinsonian medications. For possible PD, there were only two concordant pairs, both female dizygotic. Concordances were also low in all zygotic groups when the definition of affected PD was expanded to include suspected parkinsonism or movement disorder in addition to possible PD. The best-fitting structural equation model included only environmental components of variance. The findings suggest that compared with other complex diseases, the importance of genetic factors in PD is probably low.

Source: [http://www.neurology.org/cgi/content/abstract/63/2/301](http://www.neurology.org/cgi/content/abstract/63/2/301)

Ropinirole and Restless Leg Syndrome
A recent study published in Sleep asserts that the drug, ropinirole (Requip), can bring relief to persons suffering from Restless Leg Syndrome (RLS). Sixty-five patients with at least a moderately severe form of RLS participated in the placebo-controlled parallel study of 15 research centers in US. Findings indicate that involuntary leg movements decreased from 49 per hour to 12 per hour in the drug treated groups. The placebo group showed a decrease of only 2 kicks per hour. The study found that lower dosages of ropinirole were needed to treat RLS as compared with PD. A mean dose of 1.8 mg per day taken 1-2 hours at bedtime reduced the leg movements to normal levels. Requip is under review by the FDA for an approved indication to treat.


VA Scientists Study Sleep and Brain Chemicals
Researchers at the VA Greater Los Angeles Healthcare System and UCLA discovered how three brain chemicals - serotonin, norepinephrine and histamine - play distinct roles in regulating sleep for Doberman pinchers. According to their study, serotonin and norepinephrine affect muscle tone and keeping the body still at night, while histamine controls wakefulness. During cataplexy, neurons with histamine remained active while those containing serotonin and norepinephrine were silent. In an earlier study, the same researchers found that narcoleptics had 95 percent fewer hypocretin (orexin)
nerve cells in their brains than those without the illness. These biological findings may help guide the development of new drugs to induce sleep or maintain alertness.

Source: [http://www1.va.gov/resdev/prt/va_research_currents_july_04.pdf](http://www1.va.gov/resdev/prt/va_research_currents_july_04.pdf)

**Parkinson's Disease: A Review**

A recent review of Parkinson's disease has been published in The Lancet by authors Samii, Nutt, and Ransom. The Seminar section covers the basics from terminology to aspects of diagnosis, treatment, and pathogenesis followed by an extensive reference list. Drs. Samii and Nutt are physicians in the Northwest PADRECC.

Source: [http://neurology.thelancet.com/](http://neurology.thelancet.com/)

**PD Research Advocate Dies**

Millicent Kondracke, 64, a psychotherapist whose struggle with Parkinson's disease was chronicled in a book, *Saving Millie*, by her journalist husband, Morton Kondracke, recently died in Washington, DC. The Kondracke's were active in "disease politics" - the campaign to find a cure for Parkinson's disease through advocating for increased government research funding. Source: *Washington Post, July 23, 2004.*

**PADRECC National Consortium: Online Availability**

The Consortium, established by the VA Healthcare System and the PADRECCs, serves to network VA clinicians with expertise in PD and related movement disorders. The new website is: [http://swpadrecc.neurology.ucla.edu/consortium/home.htm](http://swpadrecc.neurology.ucla.edu/consortium/home.htm)

**Houston PADRECC Educational Programs**

Patient and Family Forum: Friday, Oct. 22, 2004 11:00 AM Michael E. DeBakey VAMC

"Sleep Concerns in Parkinson's Disease" (Aliyah Sarwar, MD, speaker)

"Research Update in Parkinson's Disease" (Eugene C. Lai, MD, PhD, speaker)

Monthly Patient & Family Education/Support Group

Contact Naomi Nelson for more details about above programs (713) 794-8938

**Houston PADRECC Contact Information**

Eugene C. Lai, MD, PhD, Director

Richard K. Simpson, Jr., MD, PhD, Associate Clinical Director

Naomi D. Nelson, PhD, RN, Editor (For additions/corrections, contact naomi.nelson@med.va.gov)

2002 Holcombe Blvd., Houston, Texas 77030-4298

For Information/Appointments (713) 794-7841

Website: [http://www.va.gov/padrecc_houston/](http://www.va.gov/padrecc_houston/)
Mouse Models and PD Vaccines: Promising Results

Researchers used a mouse model for testing the influence of a vaccine on the loss of brain cells and neurodegeneration. Immune cells were taken from mice after injections of MPTP, a causative factor in neuronal degeneration. These cells were then treated with Copaxone, a drug commonly used to treat the inflammatory responses in MS. The researchers found that T cells in the treated mice migrated to the damaged area of the brain where they reduced the harmful reactions of the inflammatory microglia and dramatically increased the amount of glial-derived neurotrophic factor (GDNF) that helps prevent neurodegeneration.

Source: [http://www.ninds.nih.org](http://www.ninds.nih.org)

Pergolide and Cardiac Abnormalities

A recent study reported that pergolide (Permax) use in PD might be associated with cardiac valve regurgitation. Echocardiograms were obtained on 46 patients receiving pergolide and compared with those from an age-matched control group taken from the Framingham Study. A composite valve regurgitation score was modeled as a linear function of total milligrams lifetime use of pergolide, controlling for age. 89% of pergolide-treated patients had some degree of valvular insufficiency, particularly tricuspid and cardiac.

Source: [http://www.neurology.org/cgi/content/abstract/63/2/301](http://www.neurology.org/cgi/content/abstract/63/2/301)

Parkinson's Disease, Psychosis and Comorbidities

Twenty-five patients with PD and psychotic symptoms, divided into two groups, were compared with 25 PD patients without psychiatric comorbidities. There were no differences in age, sex, education, age of onset, or duration of illness among the 3 groups. Both psychotic groups had greater motor, functional, and frontal cognitive deficits than the control group. Psychosis was a primary predictor of caregiver burden,
whereas depressive symptoms indirectly enhanced motor impairments. Nonpsychotic psychiatric disturbances, especially affective problems, are common comorbidities in PD and deserve expert clinical attention to reduce morbidity and caregiver distress. Source: http://www.neurology.org/cgi/content/abstract/63/2/301

Pramipexole versus Levodopa
Twenty-two PD Study Group sites in the US and Canada evaluated 301 subjects in a four-year study comparing treatments in early PD. Pramipexole (Mirapex) resulted in a greater reduction of dyskinesias, drug wearing off, and on-off fluctuations. Initial treatment of levodopa resulted in a lower incidence of freezing, somnolence, edema, and better motor performance. The primary outcome was measured as the amount of time to the first occurrence of dopaminergic motor complications. After 4 years, over 50% of pramipexole subjects reached the primary endpoint as compared with almost 75% of the levodopa subjects. UPDRS scores were more improved in the levodopa group. (Boehringer/Ingelheim Pharmaceuticals, Inc. & Pfizer, Inc supported this study). Source: http://www.news-medical.net/?id=3476

Parkinson's Disease and Twins
Over 33,000 twins from the Swedish Twin Registry were interviewed by phone about the presence of movement disorders. 247 twins self-reported PD or a PD diagnosis and 517 others reported parkinsonian symptoms or the use of antiparkinsonian medications. For possible PD, there were only two concordant pairs, both female dizygotic. Concordances were also low in all zygotic groups when the definition of affected PD was expanded to include suspected parkinsonism or movement disorder in addition to possible PD. The best-fitting structural equation model included only environmental components of variance. The findings suggest that compared with other complex diseases, the importance of genetic factors in PD is probably low. Source: http://www.neurology.org/cgi/content/abstract/63/2/301

Ropinirole and Restless Leg Syndrome
A recent study published in Sleep asserts that the drug, ropinirole (Requip), can bring relief to persons suffering from Restless Leg Syndrome (RLS). Sixty-five patients with at least a moderately severe form of RLS participated in the placebo-controlled parallel study of 15 research centers in US. Findings indicate that involuntary leg movements decreased from 49 per hour to 12 per hour in the drug treated groups. The placebo group showed a decrease of only 2 kicks per hour. The study found that lower dosages of ropinirole were needed to treat RLS as compared with PD. A mean dose of 1.8 mg per day taken 1-2 hours at bedtime reduced the leg movements to normal levels. Requip is under review by the FDA for an approved indication to treat. Source: http://www.journalsleep.org/citation/sleepdata.asp?citationid=2419

VA Scientists Study Sleep and Brain Chemicals
Researchers at the VA Greater Los Angeles Healthcare System and UCLA discovered how three brain chemicals - serotonin, norepinephrine and histamine - play distinct roles in regulating sleep for Doberman pinchers. According to their study, serotonin and norepinephrine affect muscle tone and keeping the body still at night, while histamine
controls wakefulness. During cataplexy, neurons with histamine remained active while those containing serotonin and norepinephrine were silent. In an earlier study, the same researchers found that narcoleptics had 95 percent fewer hypocretin (orexin) nerve cells in their brains than those without the illness. These biological findings may help guide the development of new drugs to induce sleep or maintain alertness.

Source: [http://www1.va.gov/resdev/prt/va_research.currents.july.04.pdf](http://www1.va.gov/resdev/prt/va_research.currents.july.04.pdf)

**Parkinson's Disease: A Review**

A recent review of Parkinson's disease has been published in The Lancet by authors Samii, Nutt, and Ransom. The Seminar section covers the basics from terminology to aspects of diagnosis, treatment, and pathogenesis followed by an extensive reference list. Drs. Samii and Nutt are physicians in the Northwest PADRECC.

Source: [http://neurology.thelancet.com/](http://neurology.thelancet.com/)

**PD Research Advocate Dies**

Millicent Kondracke, 64, a psychotherapist whose struggle with Parkinson's disease was chronicled in a book, Saving Millie, by her journalist husband, Morton Kondracke, recently died in Washington, DC. The Kondracke's were active in "disease politics" - the campaign to find a cure for Parkinson's disease through advocating for increased government research funding. Source: *Washington Post, July 23, 2004.*

**PADRECC National Consortium: Online Availability**

The Consortium, established by the VA Healthcare System and the PADRECCs, serves to network VA clinicians with expertise in PD and related movement disorders. The new website is: [http://swpadrecc.neurology.ucla.edu/consortium/home.htm](http://swpadrecc.neurology.ucla.edu/consortium/home.htm)

**Houston PADRECC Educational Programs**

Patient and Family Forum: Friday, Oct. 22, 2004  11:00 AM Michael E. DeBakey VAMC
 "Sleep Concerns in Parkinson's Disease" (Aliyah Sarwar, MD, speaker)
 "Research Update in Parkinson's Disease" (Eugene C. Lai, MD, PhD, speaker)
 Monthly Patient & Family Education/Support Group
  Contact Naomi Nelson for more details about above programs (713) 794-8938

**Houston PADRECC Contact Information**

Eugene C. Lai, MD, PhD, Director
Richard K. Simpson, Jr., MD, PhD, Associate Clinical Director
Naomi D. Nelson, PhD, RN, Editor (For additions/corrections, contact naomi.nelson@med.va.gov)
2002 Holcombe Blvd., Houston, Texas 77030-4298
For Information/Appointments (713) 794-7841
Website: [http://www.va.gov/padrecc_houston/](http://www.va.gov/padrecc_houston/)